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John C. Ansel5, Ralf Paus6 and Thomas E. Scholzen7
The skin as a barrier and immune organ is exposed to omnipresent environmental challenges such as
irradiation or chemical and biologic hazards. Neuropeptides released from cutaneous nerves or skin and
immune cells in response to noxious stimuli are mandatory for a fine-tuned regulation of cutaneous immune
responses and tissue maintenance and repair. They initialize host immune responses, but are equally important
for counter regulation of proinflammatory events. Interaction of the nervous and immune systems occurs both
locally – at the level of neurogenic inflammation and immunocyte activation – and centrally – by controlling
inflammatory pathways such as mononuclear activation or lymphocyte cytokine secretion. Consequently, a
deregulated neurogenic immune control results in disease manifestation and frequently accompanies chronic
development of cutaneous disorders. The current understanding, therapeutic options, and open questions of
the role that neuropeptides such as substance P, calcitonin gene-related peptide, vasoactive intestinal peptide/
pituitary adenylate cyclase-activating polypeptide, neuropeptide Y, or others play in these events are discussed.
Progress in this field will likely result in novel therapies for the management of diseases characterized by
deregulated inflammation, tissue remodeling, angiogenesis, and neoplasm.
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PERSPECTIVES
Editor’s Note
This month’s Perspectives conclude our excursion into ‘‘the
brain–skin connection’’ (Trends Immunol, Oct 2005), and
reveal additional layers in the complex inter-system
communication that intimately intertwines the body’s largest
and most external organ with the endocrine, nervous, and
immune supersystems.
Peters and co-workers focus on the role of neuropep-
tides, such as substance P, calcitonin-gene-related peptide,
neuropeptide Y, vasoactive intestinal peptide, and brady-
kinin in skin neuroendocrinology, with emphasis on their
role in neurogenic inflammation. Next, the adrenergic and
cholinergic controls of epidermal biology are elegantly
discussed by Grando and co-workers. These authors
propose that unexpectedly many activities of epidermal
keratinocytes and melanocytes are governed by an auto-
crine network of—locally generated!—adrenergic and
cholinergic signals, and list specific dermatoses where this
neuroendocrine signal transduction network may be of
particular clinical importance. The series fittingly concludes
with Bo¨hm and co-workers, who sketch the skin’s extensive
melanocortin network–possibly the best-understood neu-
roendocrine signalling system in cutaneous biology.
The tyrant dictates of space prevent this field from being
covered as comprehensively as one would wish. Yet, while
you may rightfully lament that the serotonin–melatonin
system, and the role of prolactin, opioids, endovanilloids,
and endocannabinoids in cutaneous neuroendocrinolgy
have not been adequately covered in these pages, the
editors propose you take this as an encouragement to submit
your most exciting work on these ‘‘additional kids on the
skin neuroendocrinology block’’ to this journal, so as to
enlighten us all.
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Introduction
The skin is one of the principal sites of
host interaction with the environment
where various types of stimuli can be
received and processed by the periph-
eral and central nervous system.
Neuropeptides are known to play key
roles in mediating this interaction ever
since members of this evolutionarily
ancient, highly conserved, and very
diverse class of signaling molecules
were found within peripheral nerve
fibers (cf Peters et al., 2006). Initially,
cutaneous nerves were classified as
being either ‘‘afferent’’ controlling
eccrine functions, blood flow and hair
erection, or ‘‘efferent’’ transmitting
sensory signals to the central nervous
system (Peters et al., 2006). This con-
cept was challenged after the discovery
of the first neuropeptide, substance P
(SP), in sensory nerve fibers (Hokfelt
et al., 1975) and it was soon suspected
that SP and other sensory neuro-
peptides may have multiple bioactiv-
ities in the skin exceeding these classi-
cal functions. Subsequently, many
trophic (Tanaka et al., 1988; Haeger-
strand et al., 1989; Peters et al., 2006)
and immunomodulatory (Hosoi et al.,
1993; Black, 2002; Steinhoff et al.,
2003; Peters et al., 2006) properties
of nerve fiber and skin cell-derived
neuropeptides have been reported
(supporting Supplementary material)
in health and disease. Therefore, the
term ‘‘neuropeptides’’ is not strictly
confined to peptide mediators derived
from neurons, but is used for historical
and didactical reason.
By expressing neuropeptides and
neuropeptide receptors, nerves, resi-
dent skin cells and infiltrating migratory
immunocytes share a powerful neuro-
peptide ‘‘language’’, which enables an
interdependent communication be-
tween the central nervous system and
the skin immune systems on multiple
levels. This communication allows us
to readily adapt to our environment
but also contributes to disease when
deregulated. In this review, we will
discuss the latest scientific insights
into neuropeptide signaling in skin
and cutaneous disease pathology to
improve the long missing appreciation
of this molecule family in cutaneous
biology. We will focus on the most
common and best-studied neuropep-
tides SP, calcitonin gene-related pep-
tide (CGRP), adrenomedullin (AM),
vasoactive intestinal peptide/pituitary
adenylate cyclase-activating polypep-
tide (VIP/PACAP), neuropeptide Y, or
bradykinin (BK). This will provide the
reader with sound pathomechanistic
concepts and therapeutic strategies
especially for patients with chronic
and often frustrating to treat diseases
such as atopic dermatitis, psoriasis, or
cancer-related issues.
Keratinocytes and fibroblasts are major
targets of cutaneous neuropeptide signaling
The undecapeptide SP is a member of
the tachykinin family and shares a
precursor molecule with neurokinin A
(Severini et al., 2002). Cutaneous ef-
fects of tachykinins including SP are
mediated via at least three different
neurokinin receptors (NK1–NK3) (Schol-
zen et al., 1998; Steinhoff et al., 2003).
Human and murine keratinocytes
express functional NK1 with high affi-
nity for SP (Scholzen et al., 1998;
Steinhoff et al., 2003; Peters et al.,
2006). NK1 stimulation preferentially
leads to a phospholipase C-mediated
increase of early inositol 1,4,5-trispho-
sphate (IP3) and a late increase of IP1.
This is followed by intracellular Ca2þ -
mobilization, activation of protein
kinase C, and nuclear factor-kappa B,
without evident cross talk to cAMP/
Protein kinase A signaling (Koizumi
et al., 1992).
Keratinocytes also express functional
receptors for the neuropeptides PACAP
and VIP, which belong to the VIP/
secretin/glucagon family of peptides
(Pozo, 2003). Accordingly, VIP/PACAP
receptors VPAC1 (also termed VIP1, VIP/
PACAP type II, or PVR2) and VPAC2
(VIP2; VIP/PACAP type III; PVR3) bind
VIP and PACAP with equal affinity
(Kakurai et al., 2001; Kodali et al., 2004).
Another important player, the 37
amino-acid neuropeptide aCGRP is
generated from the calcitonin gene
RNA transcripts by alternative splicing.
It is primarily located in nociceptive
primary afferent cutaneous nerve
fibers. bCGRP, which is encoded by a
different, but closely related gene,
differs from aCGRP in three amino-
acid positions and has overlapping
biological actions (Brain and Grant,
2004). CGRP signaling through
specific receptors is slightly more com-
plex compared to other neuropeptides.
An orphan calcitonin receptor-like
receptor is responsible for ligand
binding, whereas receptor activity-
modifying proteins define receptor spe-
cifity for CGRP or AM. Specific CGRP
binding to the calcitonin receptor-like
receptor requires receptor activity-
modifying proteins 1, whereas associa-
tion of calcitonin receptor-like receptor
with receptor activity-modifying
proteins 2 or 3 constitutes an AM1 or
AM2 receptor phenotype, respectively
(Foord and Marshall, 1999). The ex-
pression of CGRP and AM receptor
components has been demonstrated in
human keratinocytes and skin fibro-
blasts, but a clear analysis of the
differentiated action of CGRP and AM
on these cells has yet to be per-
formed (Albertin et al., 2003). Both
VIP and CGRP signaling in keratino-
cytes involve cAMP induction and
Ca2þ -mobilization (Haegerstrand
et al., 1989; Takahashi et al., 1993).
Remarkably, a property shared by
many cutaneous neuropeptides ap-
pears to be their skin cell prolifera-
tion-promoting capacity. SP induces
proliferation of murine and human
keratinocytes (Tanaka et al., 1988;
Scholzen et al., 1998) and dermal
fibroblasts (Nilsson et al., 1985). In
addition, it promotes fibroblast migration
in an NK1-dependent manner (Kahler
et al., 1993). Whereas VIP as well as
CGRP either alone or in conjunction
with SP stimulate proliferation of murine
(Seike et al., 2002) and human keratino-
cytes (Takahashi et al., 1993; Kakurai
et al., 2001), the functional role of VIP
and CGRP in skin fibroblasts is less
defined. In contrast, neuropeptide Y
apparently antagonizes cAMP-induced
keratinocyte proliferation (Takahashi
et al., 1993), while by itself it has no
effect on keratinocyte proliferation or
apoptosis. Thus, since cutaneous inner-
vation is required for wound contraction
and scarless fetal wound healing in
sheep (Stelnicki et al., 2000), and the
trophic net-effect of neuropeptides in
keratinocyte and fibroblast biology ap-
pears to be proliferative, neuropeptides
may be important players in wound heal-
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ing, hyperproliferative skin disorders,
and mesenchymal dysfunctions such as
scleroderma (see also Supplementary
material).
Neuropeptide containing innervation
changes during trophic and inflamma-
tory tissue remodeling in skin
Neuropeptide-containing nerves show
striking plasticity during physio-
logical and pathophysiological tissue
remodeling processes. Due to their
keratinocyte proliferation-inducing ca-
pacities, neuropeptides were suspected
to be important players in epithelial
tissue homeostasis and remodeling of
cutaneous tissue and skin appendages.
This was confirmed initially by studies
demonstrating that SP is required to
maintain the structure of taste buds
(Lundberg et al., 1979). More recently,
the plasticity of neuropeptide-contain-
ing nerve fibers during physiologically
occurring tissue remodeling processes
has been demonstrated in hair follicle
development and cycling, a particu-
larly well-suited model for studying the
effects of neuropeptides on neuroecto-
dermal–mesodermal interactions (cf Pe-
ters et al., 2006). During cutaneous
development, growth of SP and CGRP
immunoreactive nerve fibers into the
skin is strictly controlled in a time-,
spatial- and function-dependent man-
ner (cf Peters et al., 2006). Initially,
epidermal innervation is very dense,
while it decreases and gains neuropep-
tide expression after penetration of hair
follicles through the epidermis. This
indicates a close association of skin
appendage morphogenesis, innervation
development, and sensory require-
ments (Peters et al., 2006).
While this remodeling process may
be expected during morphogenesis, it
continues into adulthood. Here, the
number of neuropeptide containing
nerve fibers increases during the early
stages of hair growth (anagen develop-
ment), decreases during hair follicle
regression (catagen), and stays low in
the resting stage (telogen) (Peters et al.,
2001) as do their contacts with mast
cells (Peters et al., 2006). These
changes are of functional relevance
for hair growth since exogenous SP,
but not VIP or CGRP promotes anagen
progression in murine skin organ cul-
ture (Peters et al., 2001) and induces
hair growth (anagen) in murine back
skin. By contrast, high-dose SP induces
dystrophic catagen in mice (Maurer
et al., 1997) and cultured human
anagen hair follicles (Peters et al.,
manuscript in preparation). These stu-
dies were the first to demonstrate
plasticity of neuropeptide containing
nerve fibers during physiologically oc-
curring tissue remodeling processes
namely the hair cycle in the adult
mammal.
In addition to this physiologically
occurring plasticity of cutaneous inner-
vation and neuro-immune interaction,
neuronal plasticity in the skin of mice
is also induced by environmental
challenges such as the exposure to
stress elicited by noise. Within 24
hours after noise exposure, the number
of nerve fibers containing neuropep-
tides and their contacts to mast cells
increase in murine back skin in
comparison to the skin of animals
not exposed to this inescapable stressor
(cf Peters et al., 2006).
This stress-induced neuronal plasti-
city occurs in telogen as well as high
anagen skin, where SPþ and CGRPþ
nerve fiber numbers are normally low
(Peters et al., 2001). The untimely
rise leads to a deleterious neurogenic
inflammatory response as described
below, with increased numbers of
degranulating mast cells and infiltrating
immunocytes such as macrophages (cf
Peters et al., 2006). The resulting net-
effect leads to apoptosis of dermal cells
and cells in the hair follicle stem
cell region and the hair bulb in an
NK1, nerve growth factor (NGF), and
mast cell dependent manner. Ulti-
mately, hair growth is prematurely
terminated or arrested in telogen (for
details, see Perspectives article by Arck
et al., 2006).
Therefore, as demonstrated in the
hair follicle as a model organ, rearran-
gement of the cutaneous sensory
nervous system during tissue remodel-
ing is a prerequisite for the skin to
adapt to environmental changes such
as temperature or noxious stimuli
(see also Supplementary material)
(Peters et al., 2006). NK1-antagonists
and NGF-neutralizing antibodies were
efficiently implemented to neutralize
negative stress effects on hair growth.
This suggests that interference with
neuropeptide signaling will prove an
effective measure in the management
of stress-associated hair loss and
future studies of cutaneous remodeling
and wound healing will benefit from
this example.
Dermatitis alters cutaneous innerva-
tion. Cutaneous innervation appears to
be changed in a number of inflamma-
tory skin diseases and disease models,
including psoriasis, allergic dermatitis,
and alopecia arreata (Pincelli et al.,
1993; Hordinsky and Ericson, 1996;
Steinhoff et al., 2003; Peters EMJ, Tobin
DJ, Hagen E, Kuhlmei A, Knackstedt M,
Peter AS et al. (2006). Stress induced
neurogenic inflammation exacerbates
allergic dermatitis in mice. FASEB J,
under review), though many of these
reports are confusing. Especially in
atopic dermatitis patients both in-
creased and decreased numbers of
neuropeptide containing nerve fibers
have been reported in skin (cf Peters
et al., under review). This discrepancy
may be due to the difficulty to acquire
homogenous human skin samples. For
example, environmental factors that
are capable of modulating neuronal
plasticity such as stress are usually not
monitored in such studies.
However, under defined inflamma-
tory conditions in the mouse, topical
or intracutaneously applied antigens
induce a long-lasting increase in
nerve density and axonal growth of
SP/CGRP-containing fibers as fast as 48
hours after induction of inflammation.
This suggests that neuropeptides are
involved in the disease develop-
ment and maintenance (Huang et al.,
2003; Peters et al., under review). This
pathogenetic knowledge can help to
increase patient understanding of their
symptoms and enhance their compli-
ance during specific and often time-
consuming therapeutic intervention.
Neuropeptides control cutaneous inert
and specific immune responses
Neuropeptides control mast cell func-
tions and orchestrate neurogenic
inflammation. SP and CGRP initialize
neurogenic inflammation, a term
coined to describe neurogenic mast
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cell degranulation with subsequent
vascular responses (Steinhoff et al.,
2003; Figure 1). The latter includes
development of rapid erythema, edema,
and increased permeability of mainly
venules, which occurs directly via NK1-
expressing endothelial cells, or indirectly
via released mast cell products induced
by SP (Steinhoff et al., 2003) (Figure 1).
In addition, CGRP, but also AM induce
long-lasting erythema, based on the
vasodilatation of mainly arterioles (Brain
and Grant, 2004). Contributing neuro-
peptides also include VIP, which effec-
tively dilates small blood vessels and like
neuropeptide Y and CGRP stimulates
mast cell degranulation and histamine-
release (Wallengren, 1997). Once trig-
gered, locally generated kinins further
enhance neurogenic skin inflammation
by additional release of SP, neurokinin A
and CGRP from cutaneous afferent
sensory neurons (Geppetti, 1993; Steinh-
off et al., 2003).
Apparently, virtually all neuropep-
tides synergize in maximizing cuta-
neous neurogenic inflammatory
responses. Thus, an overall proinflam-
matory role has been proposed parti-
cularly for SP and CGRP due to their
synergism in the initial and predomi-
nantly vascular part of the cutaneous
immune response (Brain and Grant,
2004; Grant et al., 2005). This may
have important, as yet underestimated
consequences for inflammatory skin
diseases. However, in contrast, CGRP
suppresses functions of dendritic cells
(DCs) and T cells relevant for adaptive
immunity (see below).
Neuropeptide induced release of cyto-
kines from mast cells or keratinocytes
initiates cellular infiltration. SP is
capable of triggering the release of
cytokines such as tumor necrosis fac-
tor-alpha from mast cells in an NK1
dependent manner (Ansel et al., 1993).
Keratinocyte derived IL-1 (Viac et al.,
1996) may activate cutaneous as well
as infiltrating cells and triggers the
additional axonal transport and release
of neuropeptides from sensory nerves
(Jeanjean et al., 1995; Figure 1). In
addition, mast cell maturation factors
such as IL-4 or stem cell growth factor
increase the sensitivity of bone-marrow
derived mast cells to SP by inducing
mast cell NK1 expression (van der Kleij
et al., 2003). Therefore, neuropeptides,
mast cells, and cytokines form a
triangle of paracrine activation. Subse-
quently, cytokines either alone or in
conjunction with neuropeptides initiate
cellular infiltration.
Neuropeptide-initialized hyperemia
passively contributes to inflammatory
cell recruitment by locally increasing
cutaneous blood flow. Moreover, SP
and neuropeptide Y stimulate endo-
thelial cell proliferation (Steinhoff
et al., 2003) and thus likely contribute
to angiogenesis, neovascularization,
and further increased influx of immune
cells, particularly into chronically in-
flamed tissues. Beyond this indirect
recruitment of inflammatory cells, SP
increases adhesion of immunocytes to
NK1-bearing microvascular endothelial
cells by upregulating vascular and
intercellular cell adhesion molecule 1
(Figure 1; Lindsey et al., 2000). This
directly promotes lymphocyte adhesion
and extravasation, eosinophil infiltra-
tion, and eosinophil superoxide
production (Lindsey et al., 2000; Foster
and Cunningham, 2003). SP is also
capable of stimulating natural killer
cell migration, activation, and cytotoxi-
city (Feistritzer et al., 2003). CGRP
additionally modulates leukocyte and
macrophage infiltration and is chemo-
attractive for lymphocytes (Ansel
et al., 1997).
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Figure 1. Neuropeptides are key players in neurogenic inflammation. This schematic drawing depicts
neurogenic inflammatory signaling pathways and up- and downstream regulatory and effector modules
(modified from Steinhoff et al., 2003). Along the brain–skin axis, neuropeptides are involved in cutaneous
inflammation on several levels including central transmission, neurogenic inflammation and cellular
infiltration. SP and CGRP released from sensory nerve endings upon provocation mediate mast cell
degranulation and regulate blood flow and plasma extravasation. Cytokines are recruited from
keratinocytes and mast cells to initiate subsequent cutaneous infiltration. Positive feedback loops
involving proteinase activated receptors on sensory nerve endings and neurotrophins that enhance
innervation further promote this process. Degrading enzymes expressed, for example, by schwann cells
and mast cells serve to terminate the process. Abbreviations: ATP – adenosinetrisphospate, CGRP –
calcitonin gene-related peptide, CRH – corticotropin releasing hormone, DPP IV – dipeptidyl peptidase
IV, ICAM – intercellular adhesion molecule, IFN – interferon, IL– interleukin, NEP – neutral
endopeptidase, NGF – nerve growth factor, PAR – proteinase activated receptor, SP – substance P,
TNF – tumor necrosis factor, UV – ultraviolet light, VCAM – vascular cell adhesion molecule.
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Selected neuropeptides affect antigen
presentation and T-cell activation. Not
only the skin but also primary and
secondary lymphoid organs are
densely innervated. Accordingly, in
lymph nodes, afferent neuropeptide
containing nerve fibers terminate in
the area of high endothelial venules
and in the T-cell zones (Steinman,
2004). Therefore as discussed below,
antigen presenting cells (APC) and
T-cells infiltrating the skin are subject
to stimulatory and inhibitory neuropep-
tide signaling in the skin as well as in
lymphoid tissues (Figure 2).
Importantly, APC such as macro-
phages and DC as well as T-cells
constitute extra-neuronal sources of
preprotachykinin-1 mRNA expression
and SP-release. They also express NK1
(Lambrecht, 2001; Marriott and Bost,
2001). SP promotes DC maturation
and functional activation by the upre-
gulation of MHC class II, CD40, costi-
mulatory molecules (CD80, CD86),
or IL-12 (Marriott and Bost, 2001).
Endogenously produced SP contributes
to T-cell proliferation induced by
antigens, mitogens, or T-cell receptor
ligation (Lambrecht, 2001; Scholzen
et al., 2004). In addition, SP drives
the development of a murine TH1
immune response in vivo (Scholzen
and Luger, 2004), which may switch
TH2 driven atopic dermatitis to
chronic development (Peters et al.,
under review).
Despite their activating role in
neurogenic inflammation and in con-
trast to SP, CGRP, and VIP/PACAP
inhibit interaction at the DC–T-cell
interface, Langerhans cell antigen
presentation, and antigen-dependent
T-cell activation (Hosoi et al., 1993;
Kodali et al., 2004). Langerhans cells
express VIP/PACAP receptors, display
CGRP surface binding, and an endo-
genous CGRP expression has been
suggested (He et al., 2000). In addition,
T-cells also express CGRP and CGRP or
VIP directly modulate T-cell function
(Lambrecht, 2001), which suggests the
existence of autocrine or paracrine
feedback loops. Generally, CGRP is
considered to attenuate T-cell activity
and to shift a TH1 to a TH2 cytokine
profile via cAMP/PKA signaling (Seiffert
and Granstein, 2002).
In summary, as a net effect on DC/
T-cell function, SP appears to boost
APC functions, which may serve to
avoid T-cell anergy (Lambrecht, 2001;
Marriott and Bost, 2001). By contrast,
CGRP and VIP/PACAP inhibit APC
functions (Figure 2). This suggests that
these neuropeptides differentially
fine-tune the DC–T-cell interface
during initialization and establish-
ment of adaptive immunity, although
they act synergistically and overall
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Figure 2. Neuropeptides modulate DC–TC interaction. Stimulatory and inhibitory neuropeptide
signaling holds APC–T-cell interaction in a balance (modified from Lambrecht, 2001). Antigen-presenting
DCs receive neuropeptide signals from neuronal as well as non-neuronal sources. Similar to Toll-like
receptors, TRPV family of receptors sense exogenous danger signals (capsaicin, heat, cold, pH-changes).
BK and SP via BK B2 and NK1 receptors, respectively, constitute endogenous danger signals that initialize
DC-dependent adaptive immune responses. DC maturation is accomplished by the nuclear factor-kappa
B activation-dependent induction of proinflammatory cytokines (e.g., IL-12), adhesion (CD54), and
costimulatory molecules (B7¼CD80/86; CD40), and promotion of antigen-presentation (‘‘MHC II’’).
Inhibitory non-neuronal (e.g., skin cell-derived a-melanocyte stimulating hormone – a-MSH, via
melanocortin 1 receptors – MC1) or neuronal peptides (calcitonin gene-related peptide – CGRP;
vasoactive intestinal peptide – VIP; and potentially neurokinin A – NKA) deliver signals that directly and
indirectly via cytokines (IL-10) impair DC functions including the expression of MHC II and costimulatory
molecules. In addition, DC and T-cells (TC) produce auto- and/or paracrine-acting endogenous SP and
CGRP. Neuropeptide signaling supplements cell–cell contact-dependent signals delivered by molecules
constituting the immunologic synapse and drive T-cell helper phenotype, proliferation, cytotoxicity, and
integrin expression. Neuropeptide bioactivity is controlled by the relative cellular presence of peptide
receptors and peptide-degrading peptidases (NEP – neutral endopeptidase; ACE – angiotensin-converting
enzyme) expressed on DC and T-cells.
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proinflammatory in neurogenic inflam-
mation and early phase cellular infil-
tration. Future studies have to deter-
mine, to which extent neuropeptides
may interfere with signaling pathways
induced by molecules constituting the
DC–T-cell immunologic synapse.
Neuropeptide activity depends on
enzymatic termination. Peptidases
have long been recognized as key
components of the neuropeptide
system both as activators as well as
terminators of neuropeptide activity.
They serve to cleave bioactive peptide
mediators from larger prohormone pre-
cursors to initialize inflammatory and
trophic responses. More importantly
though, a variety of ubiquitous neuro-
peptide-degrading enzymes such as
neutral endopeptidase (NEP, neprilysin,
CD10), angiotensin-converting enzyme
(CD 143) or dipeptidyl peptidase IV
(CD26) (see Supplementary material)
rapidly terminate bioactivity of neuro-
peptides released from nerve terminals
or endocrine cells. Thus, peptidase
activity prevents the development of a
neuropeptide-initialized deleterious
chronic inflammation (Figure 1).
In addition, regulation of bioavail-
ability by peptidases has been evolu-
tionary important for immediate host
defense, since a number of neuropep-
tides such as SP or AM have direct
antimicrobial properties (Brogden
et al., 2005). Moreover, peptidases
probably regulate trophic neuropep-
tide functions in tissue remodeling
processes such as keratinocyte and
melanocyte proliferation, hair cycle
control, sebaceous gland function,
and cutaneous wound healing (Black,
2002; Scholzen and Luger, 2004;
Peters et al., 2006).
Not surprising, prolonged or chronic
cutaneous inflammatory diseases are
frequently accompanied by impaired
expression and function of neuropep-
tide-degrading enzymes (Scholzen and
Luger, 2004). Given the TH1 promoting
capacities of neuropeptides such as
SP, increased activity of degrading
enzymes may specifically drive TH2
dominated skin disease (Scholzen and
Luger, 2004). Therefore, regulated
expression and activity of neuro-
peptide-degrading proteases is impor-
tant for tissue homeostasis and control
of cutaneous inert as well as adaptive
immunity.
Neuropeptides differentially modulate
immediate and delayed-type hypersensi-
tivity reactions and thereby contribute
to the development and maintenance of
cutaneous inflammatory diseases
In various models of acute (Ahluwalia
et al., 1998; Joachim et al., 2004; Grant
et al., 2005; Peters et al., 2006), but
interestingly not chronic inflammation
(Castagliuolo et al., 2002), the lack of
NK1 protected mice from inflammatory
damage. These models include dinitro-
fluorobenzene-induced allergic contact
dermatitis as a model for type IV
responses (Scholzen et al., 2004) and
ovalbumine-induced allergic dermatitis
as a model for atopic dermatitis-like
combined type I and IV responses
(Peters et al., under review).
In allergic contact dermatitis, mice
lacking NK1 display impaired neuro-
genic inflammation (Grant et al., 2005)
and reduced IL-1 dependent neutrophi-
lic infiltration (Ahluwalia et al., 1998).
In analogy to noise-stress, environmen-
tal factors such as low humidity and
unpleasant odorant inhalation are
stressors that regulate SP expression
(Hosoi and Tsuchiya, 2000) and can
also worsen allergic contact dermatitis
(Hosoi and Tsuchiya, 2000). In addi-
tion, knockout mice selectively lacking
aCGRP but not bCGRP display reduced
neurogenic inflammation (Grant
et al., 2005). In ovalbumine-induced
allergic dermatitis, stress induced by
noise-exposure modulates cutaneous
innervation and nerve fiber mast
cell contacts leading to excessive
neurogenic inflammation. A cascade
that exacerbates the dermatitis in an
NK1-dependent manner (Peters et al.,
under review).
By contrast, pleasant odorants may
have relaxing properties, decrease
SP-effects, and suppress allergic con-
tact dermatitis via as yet not defined
mechanism (Hosoi and Tsuchiya,
2000). Moreover, CGRP induced
selective tumor necrosis factor-alpha-
release from mast cells effectively
reduces cutaneous contact hypersensi-
tivity (Seiffert and Granstein, 2002).
From these observations it becomes
evident that SP via NK1 in conjunction
with other neuropeptides and cytokines
supports general proinflammatory me-
chanisms relevant for innate immunity
such as neurogenic inflammation.
This may explain exacerbation of acute
cutaneous inflammatory diseases after
environmental challenges and during
stress. SP antagonists, CGRP agonists,
and relaxation techniques may there-
fore proof useful measures in the
management of cutaneous inflamma-
tory diseases susceptible to neurogenic
inflammation induced exacerbation
(Peters et al., under review). Yet, the
undefined role of bCGRP, related pep-
tides, and their receptors requires
attention by future studies.
However, the impact of SP/NK1 on
the DC-T-cell interface also helps to
initialize adaptive immune responses
in cutaneous pathology (Grant et al.,
2005). This hypothesis is further
supported by the observation that NK1
agonists promote murine antigen
sensitization in allergic contact derma-
titis and reverse neuropeptide-induced
immunosuppression (Niizeki et al.,
1999). Consequently, pharmacologic
inhibition or genetical knockout of
NK1 not only disrupts acute inflamma-
tory responses such as neurogenic
inflammation but also impairs antigen
sensitization in vivo (Scholzen et al.,
2004). The latter could be mimicked by
adoptive transfer of DCs treated in vitro
with an NK1-antagonist indicating
that SP via NK1 affects intrinsic APC
properties relevant for the initializa-
tion of adaptive immunity (Figure 2;
Scholzen et al., 2004). In addition to
SP, B2 agonists including BK not only
induce DC maturation but also switch
a TH2 to a TH1 immune response in a
mouse model of allergic inflamma-
tion (Aliberti et al., 2003). In line
with these studies, pharmacologic B2
inhibition before antigen sensitiza-
tion impairs allergic contact dermatitis
(Scholzen and Luger, 2004).
In contrast to SP and BK, VIP,
PACAP, and CGRP by modulating the
DC–TC interface appear to counter-
balance proinflammatory neuropep-
tides in vivo (Hosoi et al., 1993;
Kodali et al., 2004). Such examples
demonstrate that the immunmodula-
tory functions of neuropeptides can
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be effectively and selectively utilized to
develop therapeutic approaches for
inflammatory diseases involving adap-
tive immunity.
Other neurocutaneous effects on
antigen sensitization are likely more
complex. DCs express a member of
the transient receptor potential channel
vanilloid (TRPV) subfamily, TRPV1, and
activation of this receptor on immature
DCs by capsaicin promotes DC ma-
turation and migration into regional
lymph nodes in vivo (Basu and Srivas-
tava, 2005). Although this could not be
confirmed in a second study (O’Con-
nell et al., 2005), this leaves the
fascinating possibility that DCs may
respond to capsaicin even in the
absence of cutaneous nerve fibers. This
would imply that impaired cutaneous
antigen sensitization and diminished
contact hypersensitivity observed in
capsaicin-denervated skin may involve
a local downregulation of DC TRPV1
expression (Basu and Srivastava, 2005).
It is tempting to speculate that TRPV
receptors and their ‘‘ligands’’ (heat,
cold, or neuroactive agents such as
capsaicin) similar to Toll-like receptors
may sense important exogenous danger
signals that directly promote APC
function and initialize adaptive immu-
nity independent from sensory nerves.
Neuronal and non-neuronal tachy-
kinins, kinins, and vanilloid-receptor
ligands may therefore be viewed as
natural endogenous adjuvants and
danger-signals for key APC of the
vertebrate immune system (Matzinger,
2002; Aliberti et al., 2003).
Dysregulation of the self-regulatory
pathways mentioned above leads to
worsening of acute or the transition
to chronic inflammatory skin diseases.
The integration of the central position
that neuro-immune interactions have in
cutaneous disease will be a challenging
task for researchers and clinicians alike
in the future development of treatment
options.
Neuropeptides in tumor development
CGRP, besides being involved in vaso-
dilatation and pain, has been shown to
be a tumorigenic factor in some can-
cers (Zhang et al., 2003). Recently, in
a mouse hind paw fibrosarcoma model
for cancer pain, a close apposition of
tumor cells and peripheral nerves was
reported (Wacnik et al., 2005). This
suggested that tumor-produced media-
tors may chronically stimulate nerve
fibers and both physical and bio-
chemical interactions between nerves
and tumor cells may contribute to
cancer-associated pain (Figure 3a;
Wacnik et al., 2005). Visual character-
ization of the actual interaction
between nerves, tumor, and their en-
vironment revealed that the density of
CGRP-immunoreactive pain afferents
within the soft-tissue tumor mass is
responsible for hyperalgesia in a CGRP
receptor-dependent way (Wacnik
et al., 2005).
Accordingly, the tumor grows along-
side and among surrounding nerve
fibers, without apparent nerve tissue
destruction or derangement. Interest-
ingly in some experimental systems,
AM inhibited apoptosis, suggesting
that AM may contribute to survival of
damaged and/or premalignant cells
(Albertin et al., 2003). Moreover, a role
of sensory fiber innervation in tumor
proliferation has been suggested
(Wacnik et al., 2005). Perineural inva-
sion is associated with increased ag-
gressiveness and recurrence among
cutaneous malignancies (Feasel et al.,
2001) and may facilitate tumor metas-
tasis. Fascinatingly in melanoma
cells, reconstitution of dipeptidyl pep-
tidase IV activity altered tumorigenicity
(Wesley et al., 1999), demonstrating
the feasibility of neuropharmacothera-
peutic intervention in tumor therapy.
Some of these potential mechanisms
may direct future investigations of
interdependent actions of neurotrophic
and tumorigenic factors released from
tumor cells and nerves, respectively,
that might participate in nociception,
angiogenesis, and tumorigenesis.
Therapeutic options derived from inter-
vention with neuropeptide signaling
pathways: a future perspective
From the above it becomes apparent
that neuropeptides shared by compo-
nents of the endocrine, the skin
immune as well as the peripheral
Pre-treatment
a
b
Post-treatment with 21 days of topical
capsaicin
ENFs
Bulge region 
of miniaturized 
scalp hair follicle
Bulge region 
of miniaturized 
scalp hair follicle
Figure 3. Target/nerve/vessel interactions are intense and respond to neuro-manipulative treatment.
(a) DsRed2-transfected fibrosarcoma cells (red), CGRP-ir nerve s (blue), and CD31-ir endothelial cells
12 days after implantation of tumor cells into the heel of a C3H/He mouse. The close proximity of
nerve fibers to tumor cells clearly supports the concept that tumor-produced mediators may chronically
stimulate nerve fibers (laser scanning confocal microscopy at  100). (b) Scalp skin of alopecia arreata
patient before (left) and after 21 days of 0.075% capsaicin cream (Zostrix HP) b.i.d. (right). In the
pretreatment scalp, PGP-immunoreactive epidermal nerve fibers (ENFs) (green) are abundant in and
Substance P (red) is sparse whereas after treatment, ENFs are almost entirely depleted. These laser
scanning confocal images were captured at 20. Scale bar¼100 mm.
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and central nervous system are released
from neuronal and non-neuronal
sources including the skin. They feed
into a complex network of interacting
mediators that modulate inflamma-
tion and growth control. Neuropeptide
signaling is controlled at the level
of release, receptor expression, and
by proteolytic peptidases. Unbalanced
pro- and anti-inflammatory neuro-
peptides (e.g., after exogenous stres-
sors) deregulate cutaneous homeostasis
and trigger or exacerbate cutaneous
diseases such as atopic dermatitis,
allergic inflammation or psoriasis.
Since neuropeptides could be regarded
as endogenous and therefore ‘‘natural’’
therapeutics that are small and capable
of penetrating the epidermal barrier,
the use of modified peptides as ther-
apeutic agonist or antagonist for the
treatment of cutaneous disorders
appears attractive. However, the func-
tional complexity of neuropeptide sig-
naling requires balancing of activating
and inhibitory functions (Figure 4) and
objective definition of time point,
combination, and dosage of inter-
vention. Nonetheless, some therapeutic
strategies derived from our present
understanding of the topic are outlined
below and may be regarded as
guidance for future investigations.
Drug delivery: smaller is better. Regu-
latory peptides are an intriguing, as yet
underestimated target for pharmaco-
logical intervention. Breakthroughs in
nano-technology have enabled the
production of topical formulations that
can cross the stratum corneum and
thus promise to multiply the yield of
testable drug candidates from the dis-
covery process (Connors and Elder,
2004). Preclinical data support the
development of formulations that
either deplete nerve fibers, or contain
antagonists against receptors for
neuropeptides, cannabinoids, vanil-
loids, cytokines, BK, adenosine, ATP,
or biogenic amines. Pharmacologic
targets may as well be NGF and
neuropeptide-activating or -degrading
peptidases. Given that activity of
sensory neurons involves multiple
mediators, combinations of agents
targeting different mechanisms may
be particularly useful. In addition to
pharmacological intervention, how-
ever, psychosocial intervention and
relaxation techniques also offer promis-
ing real, immediately available thera-
peutic options for stress-aggravated skin
diseases (Hosoi and Tsuchiya, 2000;
Black, 2002; Joachim et al., 2004).
Capsaicin and other naturally occur-
ring compounds. The neurotoxin cap-
saicin depletes sensory nerves from
neuropeptides and activates TRPVs,
particularly TRPV1 (Steinhoff et al.,
2003). TRP ion channels are promising
targets for the treatment of itch. Topical
application of capsaicin (0.075%) to
deplete SP from cutaneous nerve term-
inals also activates the TRPV1 and alters
follicular innervation (Figure 3b). The
initial burning pain and hyperalgesia
pose a challenging task in the initial
management of patient compliance.
Once this is overcome, however, the
extended treatment with topical cap-
saicin leads to a dose-dependent,
partially reversible (Simone et al.,
1998) loss of epidermal C-fibers, which
may relieve localized chronic itch
(Figure 3b) without major side effects
such as histamine-release or local
Inflammatory 
response
Stress 
experience
Mechanical 
stimulation
Chemical 
stimulation
Balanced response 
(trophic, immune, perception)
Central nervous system
HPA-axis activation
Pain/itch perception
Inert immunity activation
Antimicrobial activity
Cutaneous neurogenic 
inflammation
Specific immunity activation
Dendritic cell activation
TH1 cytokine production
TH2 cytokine production
Immunocyte infiltration
Trophism
Skin appendage growth
KC/FC proliferation/migration
Terminating 
proteases
NPY
CGRP
CGRP
CGRP
CGRP
VIP?PACAP
SP
AM
SP
SP
SP
CGRP
SP
CGRP
NPY
SP/NKA
CGRP/AM
VIP
NPY
SP
CGRP/AM
VIP
SP, BK
SP
BK
Inhibitory
neuropeptides
Activating
neuropeptides
Figure 4. Neuropeptide circuits in the control of tissue maintenance and inflammation. Activating and
inhibitory neuropeptide functions together with regulatory proteases keep the central stress-response, the
peripheral cytokine production, and the local neurogenic inflammatory response in a balance. Many
neuropeptides hereby act in a dual fashion depending on the target and signaling context. SP, BK, CGRP,
and VIP/PACAP, for example, all activate mast cells in the process of neurogenic skin inflammation. By
contrast, SP inhibits HPA-axis activation and CGRP and VIP/PACAP inhibit DC activation. Where these
circuits are broken, for example, by an overflow of stimulatory triggers disease is facilitated.
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edema (Steinhoff et al., 2003). By
contrast, menthol activates the cold-
sensitive TRPM8 and the resulting
cooling perception can relieve the itch
perception as well. The potential of
new topical formulations containing
natural compounds such as cinnamon
oil, wintergreen oil, clove oil, mustard
oil, and ginger that all activate TRPA1
may hold great promise.
UV-light triggers neuropeptide-re-
lease. There is evidence that UV
exposure of skin reduces endothelial
NK1-expression (Staniek et al., 1998),
induces epidermal hyperinnervation
and triggers SP and CGRP-release from
sensory nerves (Scholzen et al., 1999).
In addition, UV-induced CGRP-release
triggers tumor necrosis factor-alpha-
release from mast cells (Seiffert and
Granstein, 2002) and upregulates
NEP expression in melanocytes and
endothelial cells (Scholzen and Luger,
2004). In the wake of these events,
UV-released neuropeptides may first
add to UV-induced acute inflammation
but ultimately induce immunosuppres-
sion via the above-described pathways.
This response is possibly under the
control of NGF (Scholzen et al., 1999;
Seiffert and Granstein, 2002). The
widely used anti-inflammatory effects
of UV-light may therefore be contrib-
uted at least in part to UV-triggered
neuropeptide-release as this evidently
reduces, for example, cutaneous con-
tact hypersensitivity responses (Seiffert
and Granstein, 2002). Likewise, UV-
induced proteases by reducing SP
bioactivity may be beneficial for hy-
perproliferative skin diseases such as
psoriasis, which is characterized by an
increased immunoreactivity of SP-posi-
tive nerve fibers (Chan et al., 1997).
Neurokinin antagonists. As SP via NK1
acts both proinflammatory and im-
mune-stimulatory, NK1 receptors are
attractive pharmacologic targets to
neutralize neurogenic inflammation.
In modern clinical praxis, they serve
as an important adjuvant strategy
for the management of skin diseases
such as atopic dermatitis, psoriasis or
allergic contact dermatitis (Scholzen
et al., 1998; Niizeki et al., 1999;
Steinhoff et al., 2003). NK1 antagonist
treatment is suited to reduce ‘‘danger-
signaling’’ in the skin and thereby
attenuate stress-induced aggravation
of cutaneous inflammation T-cell
mediated skin diseases as discussed
above. NK1 antagonists have passed
clinical trials and are now available for
treatment of anxiety, nausea, and de-
pression as well as pain (Steinhoff et al.,
2003) and NK1 antagonist can be
successfully delivered into the skin
(Kikwai et al., 2004).
CGRP-receptor antagonists. CGRP and
associated molecules are powerful
tools to suppress antigen presentation,
and may therefore find a place in the
treatment of allergic and autoimmune
skin diseases. Accordingly, novel non-
peptide CGRP receptor antagonists
such as BIBN4096BS, which are cur-
rently on trials for the treatment of
migraine, appear to attenuate CGRP
and AM-induced cutaneous microvas-
cular responses. Future clinical derma-
tological research should therefore
employ these antagonist alone ore in
combination with neurokinin antago-
nists to neutralize neurogenic inflam-
mation (Brain and Grant, 2004; Grant
et al., 2005) or to attenuate CGRP-
mediated tumor-induced hyperalgesia
(Wacnik et al., 2005).
Neuropeptide degrading enzymes.
Regulation of neuropeptide-degrading
enzymes may have a powerful impact
on the outcome of cutaneous inflam-
matory responses. A downregulation of
endogenous proteases was observed
in response to microbial infection
(Rempel and Pulliam, 2005), which
might aid to initialize the inflammatory
response and to maintain accessibility
of cells to cell-survival ensuring growth
factors (Scholzen and Luger, 2004).
Thus, targeting neuropeptide-degrading
enzymes could be a therapeutic strat-
egy for the treatment of inflammatory
skin disease. However, increased NEP
expression during lymphocyte matura-
tion either marks immature cells or
cells sentenced to apoptotic cell death
(Scholzen and Luger, 2004). Moreover,
since enhanced neuropeptide degrada-
tion may interfere with host defense,
fine-tuning of this interventional strat-
egy will be challenging.
Neuroimmunophilin ligands. Topical
neuroimmunophilin ligand FK506 is
widely appreciated in the therapy of
chronic cutaneous inflammatory dis-
eases, particularly of atopic dermatitis.
Interestingly, besides its well-known
immunmodulatory functions relying
on calcineurin inhibition, FK506 also
stabilizes cutaneous innervation and
mast cells, and is capable of decreasing
the number of nerve fiber-mast cell
contacts in atopic dermatitis skin. The
anti-inflammatory effects of immuno-
philin ligands may thus in part derive
from their neuroprotective capacities.
This is further supported by the ob-
servation, that FK506 as well as topi-
cally applied neuroimmunophilin ligand
analogs (GPI1046 and GPI1511; Guil-
ford Pharmaceuticals, Baltimore, MD),
that lack its immunosuppressant activity,
induce hair growth in mice. This sug-
gests that the neuro-protective compo-
nent of immunophillin ligand signaling
plays a dominant role in cutaneous
tissue remodeling processes as occurring
during hair growth and potentially in
neurogenic inflammation.
Perspectives
The complexity of cutaneous neuropep-
tide signaling does not allow a plain
summary of key functions. It rather opens
a cosmos of interdependent signaling
pathways characterized by antagonistic
functions such as activation versus sup-
pression of immune responses (Figure 4).
However, below the bottom line, we
find activation of acute inert and adap-
tive immune responses, whereas conti-
nuing immune responses are suppressed.
Both features are key elements of cuta-
neous tissue remodeling processes such
as the hair cycle or allergic cutaneous
diseases such as atopic dermatitis. The
nonpharmaceutical and pharmaceutical
tools available today already provide us
with a rich toolbox for future scientific
and clinical efforts and should become
basic dermatological knowledge.
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Table S1. Distribution of neurotransmitters and
neuropeptides in mammalian skin.
REFERENCES
Ahluwalia A, De Felipe C, O’Brien J, Hunt SP,
Perretti M (1998) Impaired IL-1beta-induced
neutrophil accumulation in tachykinin NK1
receptor knockout mice. Br J Pharmacol
124:1013–5
Albertin G, Carraro G, Parnigotto PP, Conconi
MT, Ziolkowska A, Malendowicz LK et al.
(2003) Human skin keratinocytes and fibro-
blasts express adrenomedullin and its recep-
tors, and adrenomedullin enhances their
growth in vitro by stimulating proliferation
and inhibiting apoptosis. Int J Mol Med
11:635–9
Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT,
Sher A, Scharfstein J (2003) Cutting edge:
bradykinin induces IL-12 production by
dendritic cells: a danger signal that drives
Th1 polarization. J Immunol 170:5349–53
Ansel JC, Armstrong CA, Song I, Quinlan KL,
Olerud JE, Caughman SW et al. (1997)
Interactions of the skin and nervous system.
J Investig Dermatol Symp Proc 2:23–6
Ansel JC, Brown JR, Payan DG, Brown MA (1993)
Substance P selectively activates TNF-alpha
gene expression in murine mast cells.
J Immunol 150:4478–85
Arck PC, Slominski A, Theoharides TC, Peters
EMJ, Paus R (2006) Neuroimmunology of
stress: skin takes center stage. J Invest
Dermatol 126:1697–704
Basu S, Srivastava P (2005) Immunological role
of neuronal receptor vanilloid receptor 1
expressed on dendritic cells. Proc Natl Acad
Sci 102:5120–5
Black PH (2002) Stress and the inflammatory
response: a review of neurogenic inflamma-
tion. Brain Behav Immun 16:622–53
Brain SD, Grant AD (2004) Vascular actions of
calcitonin gene-related peptide and adreno-
medullin. Physiol Rev 84:903–34
Brogden KA, Guthmiller JM, Salzet M, Zasloff M
(2005) The nervous system and innate
immunity: the neuropeptide connection.
Nat Immunol 6:558–64
Castagliuolo I, Morteau O, Keates AC, Valenick L,
Wang CC, Zacks J et al. (2002) Protec-
tive effects of neurokinin-1 receptor during
colitis in mice: role of the epidermal
growth factor receptor. Br J Pharmacol 136:
271–9
Chan J, Smoller BR, Raychauduri SP, Jiang WY,
Farber EM (1997) Intraepidermal nerve
fiber expression of calcitonin gene-related
peptide, vasoactive intestinal peptide and
substance P in psoriasis. Arch Dermatol Res
289:611–6
Connors RD, Elder EJ (2004) Using a portfolio of
particle growth technologies to enable de-
livery of drugs with poor water solubility.
Drug Delivery Tech 4:78
Feasel AM, Brown TJ, Bogle MA, Tschen JA,
Nelson BR (2001) Perineural invasion of
cutaneous malignancies. Dermatol Surg
27:531–42
Feistritzer C, Clausen J, Sturn DH, Djanani A,
Gunsilius E, Wiedermann CJ et al. (2003)
Natural killer cell functions mediated by the
neuropeptide substance P. Regul Pept
116:119–26
Foord SM, Marshall FH (1999) RAMPs: accessory
proteins for seven transmembrane domain
receptors. Trends Pharmacol Sci 20:184–7
Foster AP, Cunningham FM (2003) Substance P
induces activation, adherence and migration
of equine eosinophils. J Vet Pharmacol Ther
26:131–8
Geppetti P (1993) Sensory neuropeptide release
by bradykinin: mechanisms and pathophy-
siological implications. Regul Pept 47:1–23
Grant AD, Pinter E, Salmon AM, Brain SD (2005)
An examination of neurogenic mechanisms
involved in mustard oil-induced inflamma-
tion in the mouse. Eur J Pharmacol
507:273–80
Haegerstrand A, Jonzon B, Dalsgaard CJ, Nilsson J
(1989) Vasoactive intestinal polypeptide
stimulates cell proliferation and adenylate
cyclase activity of cultured human keratino-
cytes. Proc Natl Acad Sci USA 86:5993–6
He Y, Ding G, Wang X, Zhu T, Fan S (2000)
Calcitonin gene-related peptide in Langer-
hans cells in psoriatic plaque lesions. Chin
Med J 113:747–51
Hokfelt T, Kellerth JO, Nilsson G, Pernow B
(1975) Substance P: localization in the
central nervous system and in some primary
sensory neurons. Science 190:889–90
Hordinsky MK, Ericson ME (1996) Relationship
between follicular nerve supply and alope-
cia. Dermatologic Clin 14:651–60
Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe
S, Asahina A et al. (1993) Regulation of
Langerhans cell function by nerves contain-
ing calcitonin gene-related peptide. Nature
363:159–63
Hosoi J, Tsuchiya T (2000) Regulation of cuta-
neous allergic reaction by odorant inhala-
tion. J Invest Dermatol 114:541–4
Huang CH, Kuo IC, Xu H, Lee YS, Chua KY (2003)
Mite allergen induces allergic dermatitis with
concomitant neurogenic inflammation in
mouse. J Invest Dermatol 121:289–93
Jeanjean AP, Moussaoui SM, Maloteaux JM,
Laduron PM (1995) Interleukin-1 beta in-
duces long-term increase of axonally trans-
ported opiate receptors and substance P.
Neuroscience 68:151–7
Joachim RA, Sagach V, Quarcoo D, Dinh QT,
Arck PC, Klapp BF (2004) Neurokinin-1
receptor mediates stress-exacerbated allergic
airway inflammation and airway hyper-
responsiveness in mice. Psychosom Med
66:564–71
Kahler CM, Sitte BA, Reinisch N, Wiedermann CJ
(1993) Stimulation of the chemotactic mi-
gration of human fibroblasts by substance P.
Eur J Pharmacol 249:281–6
Kakurai M, Fujita N, Murata S, Furukawa Y,
Demitsu T, Nakagawa H (2001) Vasoactive
intestinal peptide regulates its receptor
expression and functions of human kera-
tinocytes via type I vasoactive intestinal
peptide receptors. J Invest Dermatol
116:743–9
Kikwai L, Babu RJ, Kanikkannan N, Singh M
(2004) Preformulation stability of Spantide II,
a promising topical anti-inflammatory
agent for the treatment of psoriasis and
contact dermatitis. J Pharm Pharmacol
56:19–25
Kodali S, Ding W, Huang J, Seiffert K, Wagner JA,
Granstein RD (2004) Vasoactive intestinal
peptide modulates Langerhans cell immune
function. J Immunol 173:6082–8
Koizumi H, Tanaka H, Fukaya T, Ohkawara A
(1992) Substance P induces intracellular
calcium increase and translocation of pro-
tein kinase C in epidermis. Br J Dermatol
127:595–9
Lambrecht BN (2001) Immunologists getting
nervous: neuropeptides, dendritic cells and
T cell activation. Respir Res 2:133–8
Lindsey KQ, Caughman SW, Olerud JE, Bunnett
NW, Armstrong CA, Ansel JC (2000) Neural
regulation of endothelial cell-mediated in-
flammation. J Investig Dermatol Symp Proc
5:74–8
Lundberg JM, Hokfelt T, Anggard A, Pernow B,
Emson P (1979) Immunohistochemical evi-
dence for substance P immunoreactive nerve
fibres in the taste buds of the cat. Acta
Physiol Scand 107:389–91
Marriott I, Bost KL (2001) Expression of authentic
substance P receptors in murine and
human dendritic cells. J Neuroimmunol 114:
131–41
Matzinger P (2002) The danger model: a renewed
sense of self. Science 296:301–5
Maurer M, Fischer E, Handjiski B, von Stebut E,
Algermissen B, Bavandi A et al. (1997)
Activated skin mast cells are involved in
murine hair follicle regression (catagen). Lab
Invest 77:319–32
Niizeki H, Kurimoto I, Streilein JW (1999) A
substance P agonist acts as an adjuvant
to promote hapten-specific skin immunity.
J Invest Dermatol 112:437–42
Nilsson J, von Euler AM, Dalsgaard CJ (1985)
Stimulation of connective tissue cell growth
by substance P and substance K. Nature
315:61–3
O’Connell PJ, Pingle SC, Ahem GP (2005)
Dendritic cells do not transduce inflamma-
tory stimuli via the capsaicin receptor
TRPV1. FEBS Lett, 579:5135–9
Orsal AS, Blois S, Labuz D, Peters EMJ, Schaefer
M, Arck PC (2006) The Progesterone deriva-
tive dydrogesterone down-regulates Neuro-
kinin 1 receptor expression on lymphocytes,
induces a Th2 skew and exerts hypoalgesic
effects in mice. J Mol Med 84:159–67
Peters EM, Botchkarev VA, Botchkareva NV,
Tobin DJ, Paus R (2001) Hair-cycle-asso-
ciated remodeling of the peptidergic inner-
vation of murine skin, and hair growth
modulation by neuropeptides. J Invest Der-
matol 116:236–45
Peters EMJ, Arck PC, Paus R (2006) Review
Article: Hair growth inhibition by psycho-
emotional stress: a model for neural mechan-
1946 Journal of Investigative Dermatology (2006), Volume 126
EMJ Peters et al.
Neuropeptides in Cutaneous Biology
isms in hair growth control. Exp Dermatol
15:1–16
Pincelli C, Fantini F, Giannetti A (1993) Neuro-
peptides and skin inflammation. Dermatol-
ogy 187:153–8
Pozo D (2003) VIP- and PACAP-mediated im-
munomodulation as prospective therapeutic
tools. Trends Mol Med 9:211–7
Rempel HC, Pulliam L (2005) HIV-1 Tat inhibits
neprilysin and elevates amyloid beta. Aids
19:127–35
Scholzen T, Armstrong CA, Bunnett NW, Luger
TA, Olerud JE, Ansel JC (1998) Neuro-
peptides in the skin: interactions between
the neuroendocrine and the skin immune
systems. Exp Dermatol 7:81–96
Scholzen TE, Brzoska T, Kalden DH F OR,
Armstrong CA, Luger TA, Ansel JC (1999)
Effect of ultraviolet light on the release
of neuropeptides and neuroendocrine
hormones in the skin: mediators of
photodermatitis and cutaneous inflamma-
tion. J Investig Dermatol Symp Proc 4:55–60
Scholzen TE, Luger TA (2004) Neutral endopepti-
dase and angiotensin-converting enzyme –
key enzymes terminating the action of neu-
roendocrine mediators. Exp Dermatol 4:22–6
Scholzen TE, Steinhoff M, Sindrilaru A, Schwarz
A, Bunnett NW, Luger TA et al. (2004)
Cutaneous allergic contact dermatitis re-
sponses are diminished in mice deficient in
neurokinin 1 receptors and augmented by
neurokinin 2 receptor blockage. FASEB J
18:1007–9
Seiffert K, Granstein RD (2002) Neuropep-
tides and neuroendocrine hormones in ultra-
violet radiation-induced immunosuppres-
sion. Methods 28:97–103
Seike M, Ikeda M, Morimoto A, Matsumoto M,
Kodama H (2002) Increased synthesis of
calcitonin gene-related peptide stimu-
lates keratinocyte proliferation in murine
UVB-irradiated skin. J Dermatol Sci 28:
135–43
Severini C, Improta G, Falconieri-Erspamer G,
Salvadori S, Erspamer V (2002) The tachyki-
nin peptide family. Pharmacol Rev 54:
285–322
Simone DA, Nolano M, Johnson T, Wendelscha-
fer-Crabb G, Kennedy WR (1998) Intrader-
mal injection of capsaicin in humans
produces degeneration and subsequent
reinnervation of epidermal nerve fibers:
correlation with sensory function. J Neurosci
18:8947–59
Staniek V, Liebich C, Vocks E, Odia SG,
Doutremepuich JD, Ring J et al. (1998)
Modulation of cutaneous SP receptors in
atopic dermatitis after UVA irradiation. Acta
Derm Venereol 78:92–4
Steinhoff M, Stander S, Seeliger S, Ansel JC,
Schmelz M, Luger T (2003) Modern aspects
of cutaneous neurogenic inflammation. Arch
Dermatol 139:1479–88
Steinman L (2004) Elaborate interactions between
the immune and nervous systems. Nat
Immunol 5:575–81
Stelnicki EJ, Doolabh V, Lee S, Levis C, Baumann
FG, Longaker MT et al. (2000) Nerve
dependency in scarless fetal wound healing.
Plast Reconstr Surg 105:140–7
Takahashi K, Nakanishi S, Imamura S (1993)
Direct effects of cutaneous neuropeptides on
adenylyl cyclase activity and proliferation in
a keratinocyte cell line: stimulation of cyclic
AMP formation by CGRP and VIP/PHM,
and inhibition by NPY through G protein-
coupled receptors. J Invest Dermatol
101:646–51
Tanaka T, Danno K, Ikai K, Imamura S (1988)
Effects of substance P and substance K on the
growth of cultured keratinocytes. J Invest
Dermatol 90:399–401
van der Kleij HP, Ma D, Redegeld FA, Kraneveld
AD, Nijkamp FP, Bienenstock J (2003)
Functional expression of neurokinin 1
receptors on mast cells induced by IL-4
and stem cell factor. J Immunol 171:
2074–9
Viac J, Gueniche A, Doutremepuich JD, Reichert
U, Claudy A, Schmitt D (1996) Substance P
and keratinocyte activation markers: an in
vitro approach. Arch Dermatol Res
288:85–90
Wacnik PW, Baker CM, Herron MJ, Kren BT,
Blazar BR, Wilcox GL et al. (2005)
Tumor-induced mechanical hyperalgesia
involves CGRP receptors and altered
innervation and vascularization of DsRed2
fluorescent hindpaw tumors. Pain 115:
95–106
Wallengren J (1997) Vasoactive peptides in
the skin. J Investig Dermatol Symp Proc 2:
49–55
Wesley UV, Albino AP, Tiwari S, Houghton
AN (1999) A role for dipeptidyl pepti-
dase IV in suppressing the malignant pheno-
type of melanocytic cells. J Exp Med
190:311–22
Zhang HW, Iida Y, Andoh T, Nojima H, Murata J,
Saiki I et al. (2003) Mechanical hypersensi-
tivity and alterations in cutaneous nerve
fibers in a mouse model of skin cancer pain.
J Pharmacol Sci 91:167–70
www.jidonline.org 1947
EMJ Peters et al.
Neuropeptides in Cutaneous Biology
